Skip to main content
. 2023 Nov 30;38(6):1140–1148. doi: 10.1038/s41433-023-02848-7

Fig. 2. Effect of intravitreal umedaptanib pegol in treatment-naïve nAMD patients.

Fig. 2

A TEMPURA phase 2 study design and results. The top panel represents the study design. The lower panels present the baseline and primary endpoint data of CST and BCVA for subjects 03, 01, 05, 04 and 08. Note that CST and BCVA in subject 08 was not improved by rescue with aflibercept. B Dramatic drug effect in TEMPURA subject 03. a Fundus color picture. b Funds red-free picture. Extensive central macular haemorrhage (shown by arrows) at baseline (top panel) was quickly resolved after the first treatment with sustained improvement at primary endpoint month 3 (bottom panel). c Change of macular anatomy at central horizontal section in b. SD-OCT at baseline (top) and month 3 (bottom). C Coordinated change in vision (BCVA) and macular anatomy (CST) in TEMPURA subject 03. Changes of BCVA letters and CST are shown in green and blue, respectively.